Multiple clinical studies have demonstrated that HNSCC patients with PIK3CA mutations can benefit from Alpelisib (NCT02282371, NCT03292250, NCT03601507, and NCT02145312). The gene discussed is PIK3CA; the disease is head and neck squamous cell carcinoma.